

AMENDMENT

Kindly amend the application as follows.

In the Claims:

Cancel claims 1-12, without prejudice, and add the following new claims 13-27.

13. (New) A method for preventing or treating an NF κ B -associated disease or condition in a mammal, said method comprising introducing an NF κ B decoy into a cell of said mammal.

14. (New) The method of claim 13, wherein said mammal is a human.

15. (New) The method of claim 13, wherein said decoy is introduced into said cell *ex vivo*.

16. (New) The method of claim 13, wherein said decoy is introduced into said cell *in vivo*.

17. (New) The method of claim 13, wherein said decoy comprises a polynucleotide.

18. (New) The method of claim 17, wherein said decoy comprises dsDNA.

19. (New) The method of claim 14, wherein said human has or is at risk of developing ischemic reperfusion injury.

20. (New) The method of claim 14, wherein said human has or is at risk of developing myocardial infarction.

21. (New) The method of claim 14, wherein said human has or is at risk of developing inflammation.

22. (New) The method of claim 21, wherein said human has or is at risk of developing glomerulonephritis.

23. (New) The method of claim 21, wherein said human has or is at risk of developing dermatitis.

24. (New) The method of claim 14, wherein said human has or is at risk of developing immune disease.

25. (New) The method of claim 14, wherein said human has or is at risk of developing transplant rejection.

26. (New) The method of claim 14, wherein said human has or is at risk of developing a neoproliferative disorder.

27. (New) The method of claim 26, wherein said human has or is at risk of developing restenosis.